About Bioline  All Journals  Testimonials  Membership  News  Donations

Indian Journal of Pharmacology
Medknow Publications on behalf of Indian Pharmacological Society
ISSN: 0253-7613
EISSN: 1998-3751
Vol. 42, No. 3, 2010, pp. 153-156
Bioline Code: ph10046
Full paper language: English
Document type: Research Article
Document available free of charge

Indian Journal of Pharmacology, Vol. 42, No. 3, 2010, pp. 153-156

 en Comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertension
Akat, Pramod B.; Bapat, Tushar R.; Murthy, Mangala B.; Karande, Vitthal B. & Burute, Shreyas R.


Background : Theoretically, angiotensin II receptor blockers (ARBs) have certain advantages over angiotensin-converting enzyme inhibitors, but the contribution of these advantages to the clinical effect of ARBs is not known.
Objective : To compare the efficacy and tolerability of telmisartan with enalapril in patients of essential hypertension.
Materials and Methods : Patients of mild to moderate hypertension were randomized to receive either 40 mg of telmisartan or enalapril 10 mg once a day orally for 12 weeks. At each visit, the systolic blood pressure (BP), diastolic BP and heart rate of each patient were recorded. Investigations such as hemogram hemoglobin, total leucocytes count (Hb, TLC), serum creatinine, serum glutamic oxaloacetic transaminase, serum glutamic pyruric transaminase (SGOT, SGPT) random blood sugar and urine examination were performed at baseline and after 12 weeks of the treatment period.
Results : The mean reduction in systolic BP in the telmisartan/enalapril group was 26.38 ± 10.98/26.74 ± 8.24 mmHg while the mean reduction in diastolic BP in the telmisartan/enalapril group was 14 ± 2.98/9.71 ± 4.23 mmHg, respectively, at 12 weeks. When the reduction in systolic BP in the two groups was compared, there was no significant difference between the groups (P > 0.05). However, the mean reduction in diastolic BP achieved with telmisartan at 12 weeks was significantly higher (P < 0.001) than that achieved with enalapril after the corresponding period. The overall frequency of adverse-effects was similar. However, in the enalapril group, the incidence of dry cough was higher as compared to that in the telmisartan group (11.43% vs. 0%, respectively; P < 0.05).
Conclusion : Telmisartan produces a greater reduction in diastolic BP than enalapril and is free from the adverse-effect of dry cough that is commonly encountered with enalapril.

Blood pressure, diastolic BP, enalapril, hypertension, systolic BP, telmisartan

© Copyright 2010 Indian Journal of Pharmacology.
Alternative site location:

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2020, Site last up-dated on 28-Nov-2020.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Internet Data Center of Rede Nacional de Ensino e Pesquisa, RNP, Brazil